JBJuliet N. Barker

Juliet N. Barker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juliet N. Barker has a total of 258 co-authors. Here are the top co-authors by number of shared publications:

  • Andromachi Scaradavou

    Pediatric Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York

    25 shared publications
  • Nancy A. Kernan

    Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    17 shared publications
  • James William Young

    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

    15 shared publications
  • Sergio Giralt

    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

    15 shared publications
  • Marissa Lubin

    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

    14 shared publications
  • Doris M. Ponce

    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA

    13 shared publications

Latest Publications

  • Open Access

    Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients

    by Warren B. Fingrut, Stephanie Chinapen, Jessica Flynn, Angela Katrichis, Melissa Stewart, Eric Davis, Brian C. Shaffer, Gunjan L. Shah, Juliet N. Barker


  • Open Access

    Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

    by Warren B. Fingrut, Boglarka Gyurkocza, Jessica R. Flynn, Eric Davis, Sean M. Devlin, Andromachi Scaradavou, Stephanie Chinapen, Sean Quach, Christina Cho, Sergio A. Giralt, et al.

    Although alternative donors extend transplant access, whether recipient ancestry affects the time to allogeneic transplant is not established. We analyzed the likelihood of clinically significant delays to allograft by patient ancestry in 313 adult patients with acute myelogenous leukemia (AML) who underwent transplantation. Non-European ancestry patients (n = 99) were more likely than Europeans (n = 214) to receive HLA-mismatched donor allografts (45% vs 24%). Overall, the median time from transplant indication to allograft was 127 days (range, 57-1683). In multivariable analysis, non-Europeans had an increased risk of prolonged indication to transplant time >180 days owing to significant delays in indication to consult >90 days and consult to transplant >120 days. Compared with recipients of HLA-matched unrelated donors (URDs), HLA-mismatched adult donor recipients were at an increased risk of delayed indication to transplant, whereas HLA-identical sibling and cord blood recipients were at a lower risk. Subanalysis showed more indication to transplant delays >180 days in non-European (44%) vs European (19%) 8/8 URD recipients. Finally, the pandemic further exacerbated delays for non-Europeans. In summary, although non-European patients with AML are less likely to receive 8/8 URDs as expected, if they do, their transplants are delayed. HLA-identical siblings and cord blood facilitate the fastest transplants regardless of patient ancestry, whereas other adult donor transplants are delayed. Strategies to mitigate referral barriers, hasten donor evaluation, and use all alternative donor sources are critical to ensure timely transplantation for patients with AML.


  • Open Access

    Inaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and health care delivery

    by Warren B. Fingrut, Eric Davis, Stephanie Chinapen, Kristine Naputo, Ioannis Politikos, Andromachi Scaradavou, Juliet N. Barker

    Warren B Fingrut, Eric Davis, Stephanie Chinapen, Kristine A Naputo, Ioannis Politikos, Andromachi Scaradavou, Juliet N. Barker; Inaccuracies in assignment of p


  • Open Access

    An Optimized Search Prognosis Tool to Predict 8/8 HLA Allele-Matched Unrelated Donor Procurement

    by Eric Davis, Anne Archer, Jessica Flynn, Melissa Nhaissi, Candice Rapoport, Beth Suri, Deborah Wells, Esperanza Papadopoulos, Ioannis Politikos, Warren B. Fingrut, et al.


  • Open Access

    Racial disparities in access to alternative donor allografts persist in the era of “donors for all”

    by Warren B. Fingrut, Boglarka Gyurkocza, Eric Davis, Jessica Flynn, Stephanie Chinapen, Kristine A. Naputo, Sean Quach, Christina Cho, Sergio A. Giralt, Ann A. Jakubowski, et al.


  • Human cytomegalovirus expands a CD8 + T cell population with loss of BCL11B expression and gain of NK cell identity

    by Rosa Sottile, M. Kazim Panjwani, Colleen M. Lau, Anthony F. Daniyan, Kento Tanaka, Juliet N. Barker, Renier J. Brentjens, Joseph C. Sun, Jean-Benoît Le Luduec, Katharine C. Hsu

    NKG2C + CD8 + T cells, found in 40% of HCMV-seropositive individuals, have lost BCL11B expression and adopt an innate-like identity.


  • Open Access

    High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

    by Juliet N. Barker, Sean M. Devlin, Kristine A. Naputo, Kelcey Skinner, Molly A. Maloy, Lisa Flynn, Theodora Anagnostou, Scott T. Avecilla, Andromachi Scaradavou, Christina Cho, et al.

    Cord blood transplantation (CBT) after high intensity or nonmyeloablative conditioning has limitations. We investigated cyclosporine-A/mycophenolate mofetil–based intermediate intensity (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg, total body irradiation 400 cGy) unmanipulated double-unit CBT (dCBT) with prioritization of unit quality and CD34+ cell dose in graft selection. Ninety adults (median age, 47 years [range, 21-63]; median hematopoietic cell transplantation comorbidity index, 2 [range, 0-8]; 61 [68%] acute leukemia) received double-unit grafts (median CD34+ cell dose, 1.3 × 105/kg per unit [range, 0.2-8.3]; median donor-recipient human leukocyte antigen (HLA) match, 5/8 [range 3-7/8]). The cumulative incidences of sustained CB engraftment, day 180 grade III-IV acute, and 3-year chronic graft-versus-host disease were 99%, 24%, and 7%, respectively. Three-year transplant-related mortality (TRM) and relapse incidences were 15% and 9%, respectively. Three-year overall survival (OS) is 82%, and progression-free survival (PFS) is 76%. Younger age and higher engrafting unit CD34+ cell dose both improved TRM and OS, although neither impacted PFS. Engrafting unit-recipient HLA match was not associated with any outcome with a 3-year PFS of 79% in 39 patients engrafting with 3-4/8 HLA-matched units. In 52 remission acute leukemia patients, there was no association between minimal residual disease (MRD) and 3-year PFS: MRD negative of 88% vs MRD positive of 77% (P = .375). Intermediate intensity dCBT is associated with high PFS. Use of highly HLA mismatched and unmanipulated grafts permits wide application of this therapy, and the low relapse rates support robust graft-versus-leukemia effects even in patients with MRD.


  • Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

    by Gunjan L. Shah, Susan DeWolf, Yeon Joo Lee, Roni Tamari, Parastoo B. Dahi, Jessica A. Lavery, Josel Ruiz, Sean M. Devlin, Christina Cho, Jonathan U. Peled, et al.

    BACKGROUND. Understanding outcomes and immunologic characteristics of cellular therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving therapies in the COVID-19 era. In this study of recipients of allogeneic (Allo) and autologous (Auto) hematopoietic cell transplant and CD19-directed chimeric antigen receptor T cell (CAR T) therapy at Memorial Sloan Kettering Cancer Center, we aimed to identify clinical variables associated with COVID-19 severity and assess lymphocyte populations. METHODS. We retrospectively investigated patients diagnosed between March 15, 2020, and May 7, 2020. In a subset of patients, lymphocyte immunophenotyping, quantitative real-time PCR from nasopharyngeal swabs, and SARS-CoV-2 antibody status were available. RESULTS. We identified 77 patients with SARS-CoV-2 who were recipients of cellular therapy (Allo, 35; Auto, 37; CAR T, 5; median time from cellular therapy, 782 days; IQR, 354–1611 days). Overall survival at 30 days was 78%. Clinical variables significantly associated with the composite endpoint of nonrebreather or higher oxygen requirement and death (n events = 25 of 77) included number of comorbidities (HR 5.41, P = 0.004), infiltrates (HR 3.08, P = 0.032), and neutropenia (HR 1.15, P = 0.04). Worsening graft-versus-host disease was not identified among Allo recipients. Immune profiling revealed reductions and rapid recovery in lymphocyte populations across lymphocyte subsets. Antibody responses were seen in a subset of patients. CONCLUSION. In this series of Allo, Auto, and CAR T recipients, we report overall favorable clinical outcomes for patients with COVID-19 without active malignancy and provide preliminary insights into the lymphocyte populations that are key for the antiviral response and immune reconstitution. FUNDING. NIH grant P01 CA23766 and NIH/National Cancer Institute grant P30 CA008748.


  • Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin

    by Ioannis Politikos, Sean M. Devlin, Maria E. Arcila, Jonathan C. Barone, Molly A. Maloy, Kristine A. Naputo, Josel D. Ruiz, Christopher M. Mazis, Andromachi Scaradavou, Scott T. Avecilla, et al.

    Double unit cord blood (dCB) transplantation (dCBT) is associated with high engraftment rates but delayed myeloid recovery. We investigated adding haplo-identical CD34+ cells to dCB grafts to facilitate early haplo-identical donor-derived neutrophil recovery (optimal bridging) prior to CB engraftment. Seventy-eight adults underwent myeloablation with cyclosporine-A/mycophenolate mofetil immunoprophylaxis (no antithymocyte globulin, ATG). CB units (median CD34+ dose 1.1 × 105/kg/unit) had a median 5/8 unit-recipient human leukocyte antigen (HLA)-match. Haplo-identical grafts had a median CD34+ dose of 5.2 × 106/kg. Of 77 evaluable patients, 75 had sustained CB engraftment that was mediated by a dominant unit and heralded by dominant unit-derived T cells. Optimal haplo-identical donor-derived myeloid bridging was observed in 34/77 (44%) patients (median recovery 12 days). Other engrafting patients had transient bridging with second nadir preceding CB engraftment (20/77 (26%), median first recovery 12 and second 26.5 days) or no bridge (21/77 (27%), median recovery 25 days). The 2 (3%) remaining patients had graft failure. Higher haplo-CD34+ dose and better dominant unit-haplo-CD34+ HLA-match significantly improved the likelihood of optimal bridging. Optimally bridged patients were discharged earlier (median 28 versus 36 days). ATG-free haplo-dCBT can speed neutrophil recovery but successful bridging is not guaranteed due to rapid haplo-identical graft rejection.


  • Open Access

    Evaluation of Cord Blood Total Nucleated and CD34+ Cell Content, Cell Dose, and 8-Allele HLA Match by Patient Ancestry

    by Juliet N. Barker, Christopher M. Mazis, Sean M. Devlin, Eric Davis, Molly A. Maloy, Kristine Naputo, Melissa Nhaissi, Deborah Wells, Andromachi Scaradavou, Ioannis Politikos